Quince Therapeutics Quote - QNCX

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

1.9696

Bid

1.88

Offer

1.98

Volume

114,085

1.86 Day's Range 1.95

0.5116 52 Week Range 2.45

Market Cap

86.666M

Previous Close

1.88

Open

1.92

Last Trade

1.97

Last Trade Time

Financial Volume

US$ 219,572

VWAP

1.9246

Average Volume (3m)

632,089

Shares Outstanding

44,001,643

Dividend Yield

PE Ratio

-2.73

Earnings Per Share (EPS)

-0.71

Revenue

Net Profit

-31.39M

Quince Therapeutics, Inc., is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. The company's Phase 3 lead asset, EryDex, is the first product in development that leverages its proprietary Autologous Intracellular Drug ... Quince Therapeutics, Inc., is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. The company's Phase 3 lead asset, EryDex, is the first product in development that leverages its proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform, which is a novel drug/device combination that uses an automated process designed to encapsulate a drug into the patient's own red blood cells. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

quincetx.com

Headquarters

Wilmington, Delaware, USA

Founded

Quince Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker QNCX. The last closing price for Quince Therapeutics was US$1.88. Over the last year, Quince Therapeutics shares have traded in a share price range of US$ 0.5116 to US$ 2.45.

Quince Therapeutics currently has 44,001,643 shares in issue. The market capitalisation of Quince Therapeutics is US$82.72 million. Quince Therapeutics has a price to earnings ratio (PE ratio) of -2.73.

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form EFFECT - Notice of Effectiveness

Form S-3 - Registration statement under Securities Act of 1933

Form 8-K - Current report

Form SC 13D - General Statement of Acquisition of Beneficial Ownership

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Phase 3 NEAT clinical trial on track with 32 patients enrolled to date with majority of U.S. and European study sites now enrolling patients Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage...

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the...

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the...

Quince Therapeutics to Participate at Upcoming Investor Conferences

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.2196	12.5485714286	1.75	1.9698	1.74	117703	1.89377761	CS
4	0.1696	9.42222222222	1.8	2.45	1.65	182493	1.91791173	CS
12	1.2596	177.408450704	0.71	2.45	0.69	632089	1.45067577	CS
26	1.2696	181.371428571	0.7	2.45	0.5116	366345	1.26665744	CS
52	0.9596	95.0099009901	1.01	2.45	0.5116	229035	1.22100724	CS
156	-10.6504	-84.3930269414	12.62	13.7	0.5116	463482	2.27840959	CS
260	-50.0804	-96.2159462056	52.05	121.98	0.5116	458026	13.36289313	CS

QNCX - Frequently Asked Questions (FAQ)

What is the current Quince Therapeutics share price?

The current share price of Quince Therapeutics is US$ 1.9696

How many Quince Therapeutics shares are in issue?

Quince Therapeutics has 44,001,643 shares in issue

What is the market cap of Quince Therapeutics?

The market capitalisation of Quince Therapeutics is USD 82.72M

What is the 1 year trading range for Quince Therapeutics share price?

Quince Therapeutics has traded in the range of US$ 0.5116 to US$ 2.45 during the past year

What is the PE ratio of Quince Therapeutics?

The price to earnings ratio of Quince Therapeutics is -2.73

What is the reporting currency for Quince Therapeutics?

Quince Therapeutics reports financial results in USD

What is the latest annual profit for Quince Therapeutics?

The latest annual profit of Quince Therapeutics is USD -31.39M

What is the registered address of Quince Therapeutics?

The registered address for Quince Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the Quince Therapeutics website address?

The website address for Quince Therapeutics is quincetx.com

Which industry sector does Quince Therapeutics operate in?

Quince Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
FCUVFocus Universal Inc	US$ 0.9499 (174.93%)	260.93M
NITON2OFF Inc	US$ 2.6306 (145.85%)	358.28M
CRNCCerence Inc	US$ 19.33 (143.76%)	161.8M
KITTNauticus Robotics Inc	US$ 3.8249 (140.56%)	104.8M
ACONAclarion Inc	US$ 0.2984 (110.14%)	305.64M
HWHHWH International Inc	US$ 0.4621 (-28.80%)	7.43M
SMSTDefiance Daily Target 2x Short MSTR ETF	US$ 5.69 (-26.30%)	24.77M
RAINRain Enhancement Technologies Holdco Inc	US$ 5.59 (-23.42%)	161.15k
PTLEPTL Ltd	US$ 9.35 (-23.30%)	1.04M
NXUNXU Inc	US$ 0.725868 (-22.78%)	7.59M
NITON2OFF Inc	US$ 2.6306 (145.85%)	350.92M
TGLTreasure Global Inc	US$ 0.382 (101.58%)	330.82M
ACONAclarion Inc	US$ 0.2984 (110.14%)	305.59M
FCUVFocus Universal Inc	US$ 0.9499 (174.93%)	259.78M
NVDANVIDIA Corporation	US$ 144.47 (4.45%)	222.72M